<?xml version="1.0" encoding="UTF-8"?>
<p>Moreover, Ciferri and colleagues identified several amino acid residues on the PC UL128L subunits that were critical for Nrp2 (fused to an Fc) binding by using a set of 28 HCMV PCs, each carrying mutations in one of the UL128L subunits [
 <xref rid="B72-vaccines-07-00070" ref-type="bibr">72</xref>]. They showed that Nrp2 interacted with the PC at the binding sites of pUL128- (and pUL131)-specific human neutralizing mAbs (
 <xref ref-type="fig" rid="vaccines-07-00070-f004">Figure 4</xref>a,b). Mutations in pUL128 or pUL131 dramatically reduced the interaction with Nrp2, whereas mutations of pUL130 had no effect on binding [
 <xref rid="B72-vaccines-07-00070" ref-type="bibr">72</xref>]. Overall, this experimental evidence provided an in-depth insight into the features of the architecture of the PC-Nrp2 complex.
</p>
